Good
Mostly Aligned
Patient Risk:
Low
Summary
Claims provided by the AI-generated content (indications, major contraindications, multiple warnings/precautions, and several interaction/diagnostic interference statements) are supported by the supplied prescribing-information excerpts. However, boxed warnings were not evaluated because no boxed-warning text was provided in the excerpts, and the report does not fully cover dosage administration details, adverse reactions, and storage/handling due to missing label excerpts.
Category Scores
Accurate Statements
Indicated for short-term treatment (up to 8 weeks) in adults and pediatric patients 5 years of age and older for healing and symptomatic relief of erosive esophagitis (EE) associated with GERD, with pediatric safety beyond 8 weeks not established.
Label Excerpts: Section 1.1
Indicated for maintenance of healing of EE and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult GERD patients; controlled studies did not extend beyond 12 months.
Label Excerpts: Section 1.2
Indicated for long-term treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) syndrome.
Label Excerpts: Section 1.3
Contraindicated in patients with known hypersensitivity to pantoprazole sodium delayed-release tablets or any substituted benzimidazole.
Label Excerpts: Section 4
Contraindicated in patients receiving rilpivirine-containing products.
Label Excerpts: Section 4
In adults, symptomatic response to therapy does not preclude gastric malignancy.
Label Excerpts: Section 5.1
Acute tubulointerstitial nephritis: discontinue pantoprazole and evaluate if suspected.
Label Excerpts: Section 5.2
PPI therapy may be associated with increased risk of Clostridium difficile-associated diarrhea; use lowest dose and shortest duration appropriate.
Label Excerpts: Section 5.3
PPI therapy may be associated with increased risk of osteoporosis-related fractures; use lowest dose and shortest duration appropriate.
Label Excerpts: Section 5.4
Severe cutaneous adverse reactions: discontinue pantoprazole at the first signs.
Label Excerpts: Section 5.5
Avoid administration of PPIs longer than medically indicated due to reported cutaneous/systemic lupus.
Label Excerpts: Section 5.6
Generally, daily treatment over a long period (e.g., longer than 3 years) may lead to cyanocobalamin (vitamin B-12) malabsorption.
Label Excerpts: Section 5.7
Hypomagnesemia has been reported rarely; health care professionals may consider monitoring for patients expected to be on prolonged treatment.
Label Excerpts: Section 5.8
PPI use is associated with increased risk of fundic gland polyps that increases with long-term use, especially beyond one year.
Label Excerpts: Section 5.10
CgA: serum chromogranin A levels increase and healthcare providers should temporarily stop pantoprazole at least 14 days before assessing CgA levels.
Label Excerpts: Section 5.11
False-positive urine THC screening tests have been reported in patients receiving PPIs including pantoprazole.
Label Excerpts: Section 5.12
Unsupported Statements
“No boxed warning text was provided in the excerpts.”
Boxed-warning evaluation is conditional on whether the provided excerpts include boxed warnings; the AI report asserts absence of boxed warning text without proving it from the provided excerpt content.
Contradictions
Important Omissions
Boxed warnings: the AI report did not verify whether any boxed warning exists in the label because boxed-warning text was not included in the provided excerpts.
Importance:
Moderate
Dosage details and administration instructions beyond general concepts (e.g., specific dosing table dose adjustments/footnotes; missed dose instructions) were not fully enumerated in the AI report.
Importance:
Moderate
Adverse reaction specifics (listed adverse reactions/events) and monitoring recommendations tied to those adverse reactions were not directly evaluated because Section 6 content was not used in the AI claim list.
Importance:
Moderate
Use in specific populations (pregnancy, lactation, pediatric use beyond EE, geriatrics) was not evaluated because those excerpt sections were not used for claim-by-claim support in the AI report.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated AI claims that were explicitly made (indications, major contraindications, and multiple safety warnings/diagnostic interferences) appear supported by the provided label excerpts. The main limitation is incomplete coverage/evaluation of certain label components (e.g., boxed warning content, adverse reactions specifics, and some population/administration details), which affects completeness rather than identification of direct falsehoods.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Incomplete verification due to missing excerpts/coverage for boxed warnings, adverse reaction specifics, specific populations, and some administration/dosage details.
Suggested Improvement
Provide and evaluate the full boxed warning section (if present), Section 6 adverse reactions, Section 8 (pregnancy/lactation/geriatrics and pediatric indications beyond EE), and the complete Section 2 administration/missed dose and dosing-table footnotes to achieve label-level completeness.